drugset
Drugs / Mosaic gp140
last change Nov 2023 re-read 9 days ago

Mosaic gp140

Developed for
HIV infectious disease
Investigated by
Janssen Vaccines & Prevention B.V. · Beth Israel Deaconess Medical Center · Ragon Institute of MGH, MIT and Harvard · US Military HIV Research Program

Trials 2

today NCT03307915 · Ph 1 NCT02935686 · Ph 1/2
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03307915 Mar 2018 → Nov 2021 HIV infectious disease Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02935686 Mar 2017 → Nov 2023 — Janssen Vaccines & Prevention B.V. Completed No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2023-01-18 Janssen Research & Development, LLC Results Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial jnj.com ↗
The Mosaico DSMB analysis, based on the data available to date, indicated that the regimen does not protect against HIV and the study is not expected to meet its primary endpoint.
2019-07-23 Janssen Research & Development, LLC Results Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen jnj.com ↗
But notably, the study found that bivalent gp140 enhanced immune responses to Clade B, the predominant subtype in the Americas, Western Europe and Australasia.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Mosaic gp140 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02935686 ↗
1

NCT03307915 ↗
Route Intramuscular “Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.” NCT02935686 ↗